ReviewBritish journal of pharmacology2008
The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders.
Review in British journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks.British journal of pharmacology · 2014Trial
- From weather to symptoms: Preliminary links between weather and inflammation in schizophrenia.Brain, behavior, & immunity - health · 2026Article
- Multi-omics approaches to major psychiatric disorders.Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2026Review
- Extracellular vesicle approach to major psychiatric disorders.European archives of psychiatry and clinical neuroscience · 2023Review
- A longitudinal resource for studying connectome development and its psychiatric associations during childhood.Scientific data · 2022Article
- Review
- Investigating aberrantly expressed microRNAs in peripheral blood mononuclear cells from patients with treatment‑resistant schizophrenia using miRNA sequencing and integrated bioinformatics.Molecular medicine reports · 2020Article
- Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks.Molecular psychiatry · 2020Article
- Serum BICC1 levels are significantly different in various mood disorders.Neuropsychiatric disease and treatment · 2019Article
- Combined serum levels of multiple proteins in tPA-BDNF pathway may aid the diagnosis of five mental disorders.Scientific reports · 2017Article
- Innate and adaptive immunity in the development of depression: An update on current knowledge and technological advances.Progress in neuro-psychopharmacology & biological psychiatry · 2016Review
- Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.World journal of psychiatry · 2016Review
- Global research challenges and opportunities for mental health and substance-use disorders.Nature · 2015Review
- Endophenotypes in Schizophrenia for the Perinatal Period: Criteria for Validation.Schizophrenia bulletin · 2015Review
- Urine metabolomics in rats after administration of ketamine.Drug design, development and therapy · 2015Article
- Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants.Depression and anxiety · 2014Review
- Proteomic analysis of lymphoblastoid cells derived from monozygotic twins discordant for bipolar disorder: a preliminary study.PloS one · 2013Article
- Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?European archives of psychiatry and clinical neuroscience · 2012Review
- Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells.Molecular psychiatry · 2012Article
- Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers.Schizophrenia research and treatment · 2011Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia remains an elusive multifaceted disorder with all evidence of its onset and aetiology pointing to a complex interplay of genetic, nutritional, environmental and developmental factors. Although several molecular and structural abnormalities have been reported for schizophrenia, no diagnostic test or other application of clinical use has yet emerged from this research. The heterogeneity of schizophrenia symptoms and its similarity to other psychiatric disorders, the accessibility of appropriate samples and the complexity of molecular alterations have greatly slowed down research. Biomarker discovery approaches should ultimately facilitate objective diagnosis, allow the identification of at-risk individuals, predict treatment success and revolutionize drug-discovery approaches. For psychiatric disorders, large sample numbers are necessary if disease-intrinsic alterations are to be detected in an environment of high biological variability. Only recent technological advances facilitate the profiling of proteins and metabolites of large sample numbers. These approaches promise to provide interesting insights into disease mechanisms, as they enable capturing the dynamic nature of disease-related alterations. By means of parallel profiling using a multi-omics approach, we aim to disentangle the complex nature of schizophrenia's aetiology. Here, we will outline how this system-based analysis approach can contribute to the discovery of disease mechanisms in schizophrenia and in turn other psychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.